Smith & Nephew (SNN) was in advanced discussions to combine with Johnson & Johnsonâs (JNJ) orthopedics business, though a deal fell apart over who would run the enlarged company.
Smith & Nephew (SNN) refused to agree to the combined To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. Entering text into the input field will update the search result below Quick Insights Talks collapsed mostly over leadership disputes, as Smith & Nephew refused to have the merged entity led by J&Jâs orthopedics chief, Namal Nawana, which was a non-negotiable point for both parties.
The deal would have given J&J holders 50.1% and Smith & Nephew holders the rest, with Smith & Nephew paying J&J a $10 billion dividend to balance valuations. J&J is leaning toward spinning out its orthopedics business and has attracted interest from private equity firms, including potential acquisition talks with Apollo Global Management